GHRP-6 · Research brief

GHRP-6 Peptide: Research Overview, Purity Data and Where to Buy

Real Peptides Research TeamEditorial

Updated October 14, 202611 min read

58 WORDS

Short answer

GHRP-6 was synthesised twelve years before anyone cloned the receptor it binds. The hexapeptide was characterised in 1984 as a compound that triggered growth hormone release from pituitary tissue both in vitro and in vivo ( Bowers et al., Endocrinology ), yet the receptor responsible wasn't identified until 1996, and its natural ligand, ghrelin, wasn't isolated until 1999.

Key takeaways

GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, approximately 873 Da) that acts as an agonist at the GHS-R1a receptor.
The compound was characterised in 1984, twelve years before its receptor was cloned in 1996 and fifteen before ghrelin was identified as the natural ligand in 1999.
GHRP-6 and GHRH analogues such as tesamorelin act on different receptors and different second-messenger systems, so they function as comparators rather than substitutes.
Two tryptophan residues make GHRP-6 unusually sensitive to oxidation and light, which raises the stakes on amber vials, light discipline, and single-use aliquots.
A certificate of analysis is only meaningful when it is lot-specific and includes the HPLC chromatogram and mass spectrum, not just a stated purity percentage.
GHRP-6 has no approved human or veterinary indication and appears under section S2 of the WADA Prohibited List as a growth hormone secretagogue.

GHRP-6 was synthesised twelve years before anyone cloned the receptor it binds. The hexapeptide was characterised in 1984 as a compound that triggered growth hormone release from pituitary tissue both in vitro and in vivo (Bowers et al., Endocrinology), yet the receptor responsible wasn't identified until 1996, and its natural ligand, ghrelin, wasn't isolated until 1999. The tool came first. The biology caught up later.

That sequence is why GHRP-6 still earns bench space four decades on. Our team supplies research-grade peptides to academic and private laboratories, and the questions buyers ask about GHRP-6 are rarely about mechanism. They're about whether the powder in the vial matches the sequence on the label. All products are sold for laboratory research use only and are not for human consumption.

What is GHRP-6?

GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, molecular weight approximately 873 Da) classified as a growth hormone secretagogue. It acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor that binds the gut hormone ghrelin. Laboratories use it as a pharmacological probe of the ghrelin-growth hormone axis. Research use only.

The frequent over-simplification is that GHRP-6 is just 'a growth hormone peptide.' That framing misses why it still earns catalog space: GHS-R1a sits in hypothalamic and pituitary tissue, so the compound engages a central signalling node rather than a single endocrine switch. What follows covers the mechanism in research terms, what the published literature on GHRP-6 examines, bench handling and storage, how per-lot purity is documented, regulatory status, and what research supply involves.

A ghrelin mimetic, not a GHRH analogue

GHRP-6 belongs to the growth hormone secretagogue class, not the growth hormone releasing hormone class, and that single distinction governs how it behaves in a model system.

GHS-R1a is a G protein-coupled receptor that signals through Gq/11. Agonist binding activates phospholipase C, which generates inositol trisphosphate (IP3) and diacylglycerol, raising intracellular calcium in pituitary somatotroph cells. That calcium flux is the proximate trigger for growth hormone secretion. GHRH analogues such as Tesamorelin and CJC-1295 No DAC bind an entirely separate receptor, GHRHR, and signal through cyclic AMP and protein kinase A. Similar downstream readout in many models, completely different upstream pharmacology.

The sequence also explains the stability profile. Two of the six residues are D-amino acids, D-tryptophan at position two and D-phenylalanine at position five, and D-configuration residues resist the proteases that would rapidly clear an all-L hexapeptide. The C-terminal lysine carries an amide cap rather than a free carboxyl group, a standard stabilising modification in secretagogue design.

In our experience fielding supply questions, this is the most common point of confusion we see. Researchers searching for a GHRH analogue land on GHRP-6 regularly, and the two classes are not interchangeable. Comparative work pairs them deliberately rather than swapping one for the other.

What the published literature examines

The published record on GHRP-6 is dominated by its role in uncovering the ghrelin system, not by clinical outcome data. Three papers carry most of the weight.

Its original characterisation demonstrated that a synthetic hexapeptide could act on the pituitary to release growth hormone with apparent specificity (Endocrinology, 1984). Twelve years later, a receptor in pituitary and hypothalamus functioning in growth hormone release was cloned and described (Science, 1996), giving the secretagogue class a defined molecular target for the first time. The endogenous ligand for that receptor was then identified as ghrelin, an acylated peptide isolated from stomach tissue (Nature, 1999).

Read in order, those three papers explain why GHRP-6 remains catalogued as a research tool rather than a historical curiosity. It was the pharmacological key that found a lock nobody had described, and reverse pharmacology of that kind is rare.

Because ghrelin is gut-derived, the receptor it shares with GHRP-6 sits at the intersection of endocrine and metabolic research. That overlap is why the compound turns up in two literatures that rarely cite each other.

What the record does not contain is an approved indication, a recognised therapeutic use, or human outcome data. We state that plainly because the gap matters: GHRP-6 is a laboratory reagent, and describing it as something that treats or improves a condition would be false.

Handling and storage at the bench

Lyophilised GHRP-6 is held frozen, dry, and shielded from light; in solution it moves to refrigeration and a short working window. Those two states behave nothing alike.

As a white freeze-dried powder in a sealed vial with desiccant intact, GHRP-6 is stable for extended periods at minus 20°C or colder. Brief ambient exposure during transit is normal and expected for lyophilised material. Once the powder enters solution, hydrolysis of peptide bonds proceeds continuously instead of being arrested by the solid state, which is why refrigeration at 2–8°C and prompt use stop being optional.

Here's the handling detail most storage guidance skips. GHRP-6 carries two tryptophan residues, and tryptophan is among the most oxidation-prone and photolabile of the standard amino acids. Amber vials, minimal benchtop light exposure, and attention to headspace oxygen are not housekeeping for this particular sequence. They're method. A solution left under fluorescent light for several hours can lose integrity with no visible change at all.

Repeated freeze-thaw cycling is the other avoidable loss. Splitting a stock into single-use aliquots means working material thaws once rather than nine times, and each cycle concentrates solutes at the ice interface in ways that favour aggregation.

Researchers designing any in vivo model should talk to their veterinarian and clear the design with their institutional animal care and use committee before material is ordered.

How purity gets verified, lot by lot

Purity for GHRP-6 is established by reversed-phase high-performance liquid chromatography (HPLC), and identity is confirmed by mass spectrometry, with both results tied to one specific synthesis lot on a certificate of analysis.

HPLC separates the target peptide from truncated sequences, deletion products, and residual synthesis reagents, then reports the target as a percentage of total peak area. Mass spectrometry measures molecular weight against the theoretical value for the GHRP-6 sequence, which is how a mislabelled or substituted peptide gets caught before it reaches a bench.

A usable certificate shows the lot number, synthesis date, the full amino-acid sequence, molecular formula and theoretical mass, purity by HPLC, and the chromatogram and mass spectrum themselves. Not a summary of them. The traces.

A purity figure printed on a product page with no lot number and no chromatogram is a marketing statement, not a document of record. The chromatogram matters more than the headline number, because it shows what the impurity peaks are, not merely how much of the vial they occupy. Two lots at the same stated purity can carry completely different impurity profiles.

Every lot we release carries its own certificate, published rather than supplied on request, and they sit on our certificates of analysis page. Our team runs small-batch synthesis for exactly this reason. Smaller lots mean each certificate describes a narrower population of vials, and traceability stops being approximate.

Regulatory status and ordering for research

GHRP-6 is not an FDA-approved drug, is not a dietary supplement ingredient, and is supplied strictly as a research chemical for laboratory use. No regulatory authority has evaluated it for any human or veterinary indication.

That status has practical consequences. There is no compendial monograph setting analytical standards for GHRP-6, so rigour is a supplier choice rather than a regulatory floor. The World Anti-Doping Agency lists growth hormone secretagogues under section S2 of its Prohibited List, which covers peptide hormones and growth factors, and any institution working with competitive athletes should treat that classification as binding.

Research supply differs from retail in documentation rather than packaging. Laboratories sourcing GHRP-6 should expect a lot-specific certificate, sequence verification that holds consistent between orders, and a supplier able to answer analytical method questions without deflecting. Specification details for the current lot sit on our GHRP-6 product page, and the broader research peptide catalog covers related compounds for comparative work, including Ipamorelin.

One operational note from our side: the laboratories that have the fewest problems are the ones recording lot numbers in their notebooks alongside experimental conditions. When a result looks anomalous six months later, that single column of data separates a reagent question from a biology question.

Selection between secretagogues usually comes down to receptor target and how narrow a response the model requires. This table sets out how GHRP-6 sits against the compounds researchers most often evaluate beside it.

Compound	Receptor target and class	What distinguishes it in research models	Bottom line for lab selection
GHRP-6	GHS-R1a agonist, ghrelin-mimetic hexapeptide	The original secretagogue, and the probe that led to identification of the receptor in 1996	The reference compound when the research question concerns the ghrelin receptor itself rather than growth hormone output alone
GHRP-2	GHS-R1a agonist, synthetic hexapeptide	A later-generation secretagogue acting at the same receptor with a different amino-acid sequence	Useful as a within-class comparator when a study design needs two distinct GHS-R1a ligands
Ipamorelin	GHS-R1a agonist, pentapeptide	Shorter pentapeptide structure, frequently selected where a narrower secretagogue profile is wanted	The choice when the model calls for a more selective GHS-R1a tool rather than a broad one
Tesamorelin	GHRH receptor agonist, GHRH analogue	Acts on a separate receptor entirely, signalling through cyclic AMP and protein kinase A	Not a substitute for GHRP-6; it belongs in a study as a contrast arm, never as a replacement

What If: Laboratory Scenarios Researchers Actually Face

What if a vial arrives at room temperature?

Check that the material is still a dry, intact cake with the desiccant present, then move it to minus 20°C. Lyophilised peptides tolerate ambient transit because the solid state slows the hydrolysis that degrades peptides in solution. The failure mode worth looking for isn't warmth, it's moisture. A cake that has slumped, dissolved at the edges, or turned tacky indicates a seal breach, and that is worth raising with the supplier before the vial is opened.

What if the certificate has no lot number on it?

Request the lot-specific document before any use. A certificate without a lot number cannot be matched to the vial in hand, which means it documents nothing verifiable about that material. Suppliers running real quality systems publish per-lot certificates as standard practice. If a request produces a generic PDF reused across every batch, that is information about the supplier rather than about the peptide.

What if a solution looks cloudy or faintly yellow?

Stop using it and document what you observe. Cloudiness in a solution of GHRP-6 suggests aggregation or particulate contamination, and yellowing points toward oxidative change, which the two tryptophan residues in this sequence make entirely plausible. Neither appearance is diagnostic on its own, and neither can be corrected at the bench. The material should be discarded and the storage history reviewed for a light or temperature excursion.

What if two suppliers quote the same purity figure?

Compare the chromatograms, not the numbers. Two lots of GHRP-6 can report identical HPLC purity and carry completely different impurity profiles, because the figure is a percentage of total peak area and says nothing about what the remaining peaks contain. Ask for the trace and the analytical method used to generate it. A supplier who publishes chromatograms openly has already answered the question.

The unglamorous truth about secretagogue sourcing

Here's the honest answer: with GHRP-6, the sequence is not the hard part. Solid-phase synthesis of a hexapeptide is routine chemistry, and plenty of facilities can produce it. What varies enormously is whether anyone verified the result and documented it in a form a third party can check. The failure mode in this market is almost never an exotic contaminant. It's a correct GHRP-6 peptide at a lower purity than claimed, shipped against a certificate belonging to some other lot. That's a paperwork problem wearing a chemistry costume, and it is entirely preventable.

Related pages across the catalog: review current-lot specification details on the GHRP-6 product page, compare it against GHRP-2 for within-class work, read the published certificates of analysis, see how we define pure peptides, browse the full research peptide shop, or check location and shipping information.

GHRP-6 occupies an unusual position in peptide science: it is a compound that explained itself backwards. It worked first, and the receptor, the hormone, and the entire ghrelin system were found afterward by chasing why it worked. That history is a useful reminder that a research tool's value lies in what it can reveal, not in what it promises. Judge any GHRP-6 vial by the chromatogram attached to it, because the molecule is only ever as informative as the documentation standing behind it. All products are sold for laboratory research use only and are not for human consumption.

References

Peer-reviewed sources on GHRP-6 indexed in PubMed, listed for research context. Real Peptides supplies GHRP-6 for laboratory research use only.

Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis. International immunopharmacology, 2026. PMID 41534456. doi:10.1016/j.intimp.2026.116204
Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. Journal of nanobiotechnology, 2025. PMID 41327290. doi:10.1186/s12951-025-03888-9
Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Frontiers in pharmacology, 2024. PMID 38873418. doi:10.3389/fphar.2024.1402138
Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. International wound journal, 2018. PMID 29464859. doi:10.1111/iwj.12895
Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plastic surgery international, 2016. PMID 27200188. doi:10.1155/2016/4361702
Epidermal growth factor and growth hormone-releasing peptide-6: combined therapeutic approach in experimental stroke. Restorative neurology and neuroscience, 2013. PMID 23314006. doi:10.3233/RNN-120262
Growth hormone releasing peptide-6 acts as a survival factor in glutamate-induced excitotoxicity. Journal of neurochemistry, 2006. PMID 17076656. doi:10.1111/j.1471-4159.2006.04122.x
Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. Journal of pediatric endocrinology & metabolism : JPEM, 1996. PMID 8887178

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of roughly 873 Da. It is classified as a growth hormone secretagogue and acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), the receptor that also binds the gut hormone ghrelin. It is supplied for laboratory research use only.

Both are synthetic hexapeptides acting as agonists at the same GHS-R1a receptor, so they sit in the same pharmacological class. They differ in amino-acid sequence, which is why studies sometimes include both as within-class comparators rather than treating them as duplicates. GHRP-6 carries the longer research history because it was the probe compound involved in identifying the receptor in the first place.

No. GHRP-6 is not approved by the FDA for any human or veterinary indication, is not a dietary supplement ingredient, and has no compendial monograph setting analytical standards. It is sold strictly as a research chemical for laboratory use and is not for human consumption.

Purity is measured by reversed-phase high-performance liquid chromatography (HPLC), which separates the target peptide from truncated sequences, deletion products, and residual reagents and reports the target as a percentage of total peak area. Identity is confirmed separately by mass spectrometry against the theoretical molecular weight for the sequence. Both results should appear on a certificate tied to one specific synthesis lot.

A usable certificate shows the lot number, synthesis date, full amino-acid sequence, molecular formula and theoretical mass, HPLC purity, and the chromatogram and mass spectrum themselves rather than a summary of them. A purity percentage with no lot number and no trace attached is a marketing statement, not a record. Real Peptides publishes per-lot certificates on its COAs page rather than supplying them only on request.

GHRP-6 is sold to researchers, laboratories, and institutions for in vitro and documented research applications only. It is not sold for human or veterinary consumption, and no supplier can legitimately provide administration guidance for it. Anyone planning in vivo model work should talk to their veterinarian and obtain institutional animal care and use committee clearance before ordering.

As a sealed, freeze-dried powder with desiccant intact, it is held at minus 20°C or colder and protected from light. Brief ambient exposure during shipping is normal for lyophilised material. Once in solution it belongs at 2–8°C with a short working window, because hydrolysis of peptide bonds proceeds continuously in the liquid state rather than being arrested as it is in a solid.

The sequence contains two tryptophan residues, and tryptophan is among the most oxidation-prone and photolabile of the standard amino acids. That makes amber vials, limited benchtop light exposure, and attention to headspace oxygen part of the method rather than general good practice. A solution can degrade under fluorescent light with no visible change in appearance.

No, and conflating the two is the most common sourcing error we see. GHRP-6 binds GHS-R1a and signals through Gq/11, phospholipase C, and intracellular calcium. Tesamorelin and CJC-1295 bind the GHRH receptor and signal through cyclic AMP and protein kinase A. They are separate receptor systems, which makes them contrast arms in a study design, not substitutes.

The World Anti-Doping Agency lists growth hormone secretagogues under section S2 of its Prohibited List, which covers peptide hormones, growth factors, and related substances. GHRP-6 falls within that class by mechanism. Any institution conducting research involving competitive athletes should treat the classification as binding on its study design and sample handling.

Research supply differs from retail in documentation rather than packaging. A laboratory should expect a lot-specific certificate of analysis, sequence verification that stays consistent between orders, and a supplier willing to discuss synthesis and analytical method openly. Current-lot specification details are listed on the GHRP-6 product page, with related compounds available through the wider research peptide shop.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA